Virpax Pharmaceuticals, Inc.
VRPX · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.13 | 0.05 | 0.33 |
| FCF Yield | -7.10% | -5.53% | -6.63% | -6.27% |
| EV / EBITDA | -11.48 | -42.24 | -6.62 | -36.76 |
| Quality | ||||
| ROIC | 371.51% | 93.80% | 123.76% | 272.17% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.85 | 2.23 | 0.48 | 2.40 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 35.77% | -171.92% | 78.74% | -156.66% |
| Safety | ||||
| Net Debt / EBITDA | 0.45 | 0.01 | 0.54 | 0.57 |
| Interest Coverage | 0.00 | -20.75 | -314.40 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |